Skip to main content
SpringerLink
Log in
Book cover

Male Reproductive Function pp 157–172Cite as

Androgen Replacement Therapy, Risks and Benefits

  • Chapter

Part of the book series: Mineralogical Society Series ((ENDO,volume 5))

Abstract

The primary goal of androgen replacement therapy is to develop and maintain male sexual characteristics and sexual function, as well as to preserve anabolic effects on nonreproductive organs such as maintenance of muscle and bone mass (Bhasin et al, 1995; Wang and Swerdloff, 1997; Nieschlag and Behre, 1990,1998). Testosterone (T) formulations are predominantly used for androgen replacement therapy for hypogonadal men. Occasionally, supraphysiological (pharmacological) doses of androgen are administered for their anabolic effects. The use of androgens in the absence of medical indications (androgen abuse) for sports and body building purposes are discussed in Chapter 11.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Alexander GM, Swerdloff RS, Wang C, Davidson T, McDonald V, Steiner B, Heines M. Androgen-behavior correlations in hypogonadal men and eugonadal men: II. Cognitive behavior. Hormones and Behavior 1998; 33:85–94.

    Article  PubMed  CAS  Google Scholar 

  • Anderson RA, Bancroft J, Wu FC. The effects of exogenous testosterone on sexuality and mood of normal men. J Clin Endocrinol Metab 1992; 75:1503–1507.

    Article  PubMed  CAS  Google Scholar 

  • Archer J. The influence of testosterone on human aggression. Br J Psychol 1991 82:1–28.

    PubMed  Google Scholar 

  • Arias IM. The effects of anabolic steroids on liver function. In: Gross F, ed. Protein Metabolism. Berlin: Springer-Verlag, 1962:434–445.

    Google Scholar 

  • Bagatell CJ, Heiman JR, Matsumoto AM, Rivier JE, Bremner WJ. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. J Clin Endocrinol Metab 1994; 79:561–567.

    Article  PubMed  CAS  Google Scholar 

  • Behre HM, Klienh S, Leifke E, Link TM, Nieschlag E. Long term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997; 82:2386–2390.

    Article  PubMed  CAS  Google Scholar 

  • Behre HM, Nieschlag E. Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. J Clin Endocrinol Metab 1992:75:1204–1210.

    Article  PubMed  CAS  Google Scholar 

  • Besa EC. Hematologic effects of androgens revisited: an alternative therapy in various hematologic conditions. Serum Hematol 1994; 31:138–145.

    Google Scholar 

  • Bhasin S, Gabelnick HL, Spieler JM, Swerdloff RS, Wang C. Pharmacology, Biology and Clinical Application of Androgens. Wiley-Les, New York, 1996.

    Google Scholar 

  • Bhasin S, Storer tW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335:1–7.

    Article  PubMed  CAS  Google Scholar 

  • Bhasin S, Storer TW, Berman N, Yarasheski K, Clevenger B, Phillips J, Lee WP, Bunnell TJ, Casaburi R. Testosterone replacement increases fat free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997; 82:407–13.

    Article  PubMed  CAS  Google Scholar 

  • Bhasin S, Swerdloff RS, Steiner B, Peterson MA, Meridores T, Galmirini M, Pandian MR, Goldberg R, Berman N. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men. J Clin Endocrinol Metab 1992; 74:75–83.

    Article  PubMed  CAS  Google Scholar 

  • Brodoky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab 1996; 81:3469–3485.

    Article  Google Scholar 

  • Bulter GE, Sellar RE, Walker RF, Hendry M, Kelnar CI, Wu fC. Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth. J Clin Endocrinol Metab 1992; 75:37–44.

    Article  Google Scholar 

  • Burris AS, Banks SM, Carter CS, Davidson TM, Sherins RJ. A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. JAndrol 1992; 13:297–304.

    CAS  Google Scholar 

  • Cantrill JA, Davis P. Laya DM, Newman M, Anderson DC. Which testosterone replacement therapy? Clin Endocrinol (Oxf) 1984; 21:97–107.

    CAS  Google Scholar 

  • Christiansen K, Knussman R. Androgen levels and components of aggressive behavior in men. HormBehav 1987a; 21:170–180.

    CAS  Google Scholar 

  • Christiansen K, Knussman R. Sex hormones and cognitive functioning in men. Neurospychobiology 1987b; 18:27–36.

    CAS  Google Scholar 

  • Cunningham GR, Cordero E, Thornby JI. Testosterone replacement with transdermal therapeutic systems. Physiological serum testosterone and elevated dihydrotestosterone levels. JAMA 1989; 261:2525–2530.

    Article  PubMed  CAS  Google Scholar 

  • Dabs JM. Testosterone, aggression and delinquency. In Bhasin S, Gabelnick H, Spieler J, Swerdloff RS, Wang C (eds). Pharmacology, Biology and Clinical Aapplication of Androgens. Wiley-Liss: New York 1995; pp 179–189.

    Google Scholar 

  • Davis SR, Burger HG. Use of androgens in postmenopausal women. Curr Opin Obstet Gynecol 1997; 9:177–180.

    PubMed  CAS  Google Scholar 

  • De Lignieres B. Transdermal dihydrotestosterone treatment of ‘andropause’. Ann Med 1993; 25:235–241.

    PubMed  Google Scholar 

  • De Lorimier AA, Gordon GS, Lower RC, Carbone JV. Methyltestosterone, related steroids, and liver function. Arch Int Med 1965; 116:289–294.

    Google Scholar 

  • Dobs AS, Hoover DR, Chen MC, Allen R. Pharmacokinetic characteristics, efficacy and safety of buccal testosterone in hypogonadal males: a pilot study. J clin Endocrinol Metab 1998; 83:33–39.

    Article  PubMed  CAS  Google Scholar 

  • Edwards JP, Zhi L, Poolay CL, Tagley CM, West SJ, Wang MW, Gottarchis MM, Pathirama C, Shrader WT, Jones TK. Preparation, resolution, and biological evaluation of 5-aryl-l, 2-dihydro-5H-chromeno [3,4-f]quinolines:potent, orally active, nonsteroidal progesterone receptor agonists. J Med Chem 1998; 41:2779–2785.

    Article  PubMed  CAS  Google Scholar 

  • Findlay JC, Place VA, Snyder PJ. Transdermal delivery of testosterone. J Clin Endocrinol Metab 1987; 64:266–268.

    Article  PubMed  CAS  Google Scholar 

  • Finkelstein J. Androgens and osteoporosis. Clinical Aspects. In Bhasin S, Gabelnick HL, Spieler JM, Swerdloff RS, Wang C (eds) Pharmacology, Biology and Clinical Application of Androgens. Wiley-Less, New York, 1995; pp 265–277.

    Google Scholar 

  • Finkelstein JW, Susman EJ, Chinchilli WM, Kunselman SJ, D’Arcangelo MR, Schwab J, Demers JM, Liben LS, Lookingbill G, Kulin AE. Estrogen or testosterone increases self-reported aggressive behaviors in hypogonadal adolescents. J Clin Endocrinol Metab 1997; 82:2433–2438.

    Article  PubMed  CAS  Google Scholar 

  • Friedl KE, Hannan CJJ, Jones RE, Plymate SR. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism 1990; 39:69–74.

    Article  PubMed  CAS  Google Scholar 

  • Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. J Androl 1994; 15:212–215.

    PubMed  CAS  Google Scholar 

  • Gooren LJ. Androgen levels and sex functions in testosterone-treated hypogonadal men. Arch Sex Behav 1987; 16:463–473.

    Article  PubMed  CAS  Google Scholar 

  • Gould DJ, Canliffe WJ, Smiddy EG. Anabolic steroids in hereditary angioedema. Lancet 1978; 1:770–771.

    Article  PubMed  CAS  Google Scholar 

  • Griffin JE, Wilson JD. Disorders of the testes and the male reproductive tract. In Williams Textbook of Endocrinology, Wilson JD, Foster DW, Kronenberg HM, Larsen PR (eds), W B Saunders; Philadelphia, 1998, pp 819-873.

    Google Scholar 

  • Grinspoon S, Corcoran C, Askari H, Schoenfeld D, Wolf L, Burrows B, Walsh M, Hayden D, Parlman K, Anderson E, Basgoz N, Klibanski A. Effects of androgen administration in men with AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 129:18–26.

    PubMed  CAS  Google Scholar 

  • Hamann LG, Higuchi RI, Zhi L, Edwards JP, Wang XN, Marschke KB, Kong JW, Farmer LJ, Jones TK. Syntheses and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono [5,6-g] quinolines. J Med Chem 1998; 41:623–639.

    Article  PubMed  CAS  Google Scholar 

  • Handelsman DJ, Conway AJ, Boylan LM. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab 1990; 71:216–222.

    PubMed  CAS  Google Scholar 

  • Janowsky JS. Oviatt SK, Orwell KS. Testosterone influences spatial cognition in older men. Neurosc 1994; 108:325–332.

    CAS  Google Scholar 

  • Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. 1996; 81:4358–4365.

    CAS  Google Scholar 

  • Krauss DJ, Taub HA, Lantinga LJ, Dunsky MH, Kelly CM. Risks of blood volume changes in hypogonadal men treated with testosterone enanthate for erectile impotence. J Urol 1991; 146:1566–1570.

    PubMed  CAS  Google Scholar 

  • Kumar N, Didolkar AK, Monder C, Bardin DW, Sundaram K. The biological activity of 7 alpha-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone. Endocrinology 1992; 130:3677–3683.

    Article  PubMed  CAS  Google Scholar 

  • Marin P, Lonn L, Andersson B, Oden B, Olbe L, Bengtsson B, Bjorntorp P. Assimilation of triglycerides in subcutaneous and intraabdominal adipose tissue in vivo in men: effect of testosterone. J Clin Endocrinol Metab 1996; 81:1018–1022.

    Article  PubMed  CAS  Google Scholar 

  • Matsumoto AM, Sanblom RE, Schoene RB, Lee KA, Giblin EC, Pierson DJ, Bermner WJ. Testosterone replacement in hypogonadal men: effects on obstructive sleep apnea, respiratory drives and sleep. Clin Endocrinol 1985; 22:713–721.

    CAS  Google Scholar 

  • McDonnell DP, Norris JD. Analysis of the molecular pharmacology of estrogen receptor agonists and antagonists provides insights into the mechanism of action of estrogen in bone. Osteopros Int 1997; 7:S29–S34.

    Article  Google Scholar 

  • Meikle AW, Mazer NA, Moellmer JF, Stringham JD, Tolman KG, Sanders SW, Odell WD. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and the metabolites in hypogonadal men. J Clin Endocrinol Metab 1992; 74:623–628.

    Article  PubMed  CAS  Google Scholar 

  • Morishima A, Grumback MM, Simpson ER, Fisher C, Qui K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995; 80:3689–3698.

    Article  PubMed  CAS  Google Scholar 

  • Muurahainen N, Mulligan K. Clinical trials update in human immunodeficiency virus wasting. Semin Oncol 1998; 25:104–111.

    PubMed  CAS  Google Scholar 

  • Nieschlag E, Behre HM (eds). Testosterone: Action, Deficiency, Substitution. Berlin: Springer-Verlag, 1990 (1st edition), 1998 (2nd edition).

    Google Scholar 

  • Nieschlag E, Mauss J, coert A, Kicovic PM. Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate. Acta Endocrinol (Copenh) 1975; 79:366–374.

    CAS  Google Scholar 

  • O’Carroll R, Shapiro C, Bancroft J. Androgens, behaviour and nocturnal erection in hypogonadal men: the effects of varying the replacement dose. Clin Endocrinol (Oxf) 1985; 23:527–538.

    CAS  Google Scholar 

  • Salehian B, Wang C, Alexander G, Davidson T, McDonald V, Berman N, Dudley RE, Ziel F, Swerdloff RS. Pharmacokinetics, bioefficacy and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate—a clinical research center study. J Clin Endocrinol Metab 1995; 80:3567–3575.

    Article  PubMed  CAS  Google Scholar 

  • Sands R, Studd J. Exogenous androgens in postmenopausal women. Am J Med 1995; 98:76S–79S.

    Article  PubMed  CAS  Google Scholar 

  • Scaramelli JJ, Brown WA. Serum testosterone and agressiveness in hockey players. Psychosom Med 1978; 40:262–265.

    Google Scholar 

  • Schaison G, Nahonl K, Couzinet B. Percutaneous dihydrotestosterone (DHT) treatment. In Nieschlag E, Behre HM (eds). Testosterone: action deficiency, substitution. Berlin: Springer Verlag, 1990; pp 155–164.

    Google Scholar 

  • Sheffer AL, Fearon DT, Austen KF. Methyl testosterone therapy in hereditary angioedema. Ann Int Med 1997; 86:306–308.

    Google Scholar 

  • Sherwin BB. Use of combined estrogen-androgen preparations in the postmenopause: evidence from clinical studies. Int J Fertil Womens Med 1998; 43:98–103.

    PubMed  CAS  Google Scholar 

  • Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994;331:1056–1061.

    Article  PubMed  CAS  Google Scholar 

  • Snyder PJ, Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 1980; 51:1335–1339.

    Article  PubMed  CAS  Google Scholar 

  • Sokol RZ, Palacios A, Campfield LA, Saul C, Swerdloff RS. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril 1982; 37:425–430.

    PubMed  CAS  Google Scholar 

  • Stepan JJ, Lachman M, Zverina J, Pacovsky V, Baylink DJ. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 1987; 69:523–527.

    Article  Google Scholar 

  • Sweeney EC, Evans DJ. Hepatic lesions in patients treated with synthetic anabolic steroids. J Clin Path 1976; 29:626–633.

    PubMed  CAS  Google Scholar 

  • Wang C and Swerdloff RS. Androgen replacement therapy. Ann Med 1997; 29:365–370.

    PubMed  CAS  Google Scholar 

  • Wang C, Eyre DR, Clark R, Kleinberg D, Newman C, Iranmanesh A, Veldhuis J, Dudley RE, Berman N, Davidson T, Barstow TJ, Sinow R, Alexander G, Swerdloff RS. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab 1996a; 81:3654–3662.

    Article  PubMed  CAS  Google Scholar 

  • Wang C, Alexander G, Berman N, Salahian B, Davidson T, McDonald V, Steiner B, Hull L, Callegari C, Swerdloff RS. Testosterone replacement therapy improves mood in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab 1996b; 81:3578–3583.

    Article  PubMed  CAS  Google Scholar 

  • Wang C, Iranmanesh A, Berman N, McDonald V, Steiner B, Ziel F, Paulkner SM, Dudley RC, Veldhuis D, Swerdloff RS. Comparative pharmacokinetics of three doses of percutaneous dihydrotestosterone gel in healthy elderly men. A clinical Research Center Study. J Clin Endocrinol 1998; 83:2749–2757.

    Article  CAS  Google Scholar 

  • Wang C. Androgen delivery systems: overview of existing methods and application. In Pharmacology, Biology and Clinical Applications of Androgens. Bhasin S, Gabelnick HL, Spieler JM, Swerdloff rs, wang C. Wiley-Liss, New York, 1995; pp 433–435.

    Google Scholar 

  • World Health Organization. Guidelines for the Use of Androgens in Men. Geneva: WHO; 1992.

    Google Scholar 

  • Wu FC, Farley TM, Peregoudov A, Waites GM. Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Fertil Steril 1996; 65:626–636.

    CAS  Google Scholar 

  • Zhang GY, Gu YO, Wang XH, Cui YG, Bremner WJ. Pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. J Androl, 1998; 19:761–768.

    PubMed  CAS  Google Scholar 

  • Zhi L, Tegley CM, Kallel EA, Marschke KB, Mais DE, Gottardis MM, Jones TK. 5-Aryl-1,2-dihydrochromeno [3-4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists. J Med Chem 1998; 41:291–302.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Harbor-UCLA Medical Center, Torrance, California

    C. Wang & R. S. Swerdloff

Authors
  1. C. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. S. Swerdloff
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Harbor-UCLA Medical Center, Torrance, California, USA

    Christina Wang M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Kluwer Academic Publishers

About this chapter

Cite this chapter

Wang, C., Swerdloff, R.S. (1999). Androgen Replacement Therapy, Risks and Benefits. In: Wang, C. (eds) Male Reproductive Function. Mineralogical Society Series, vol 5. Springer, Boston, MA. https://doi.org/10.1007/978-0-585-38145-9_8

Download citation

  • DOI: https://doi.org/10.1007/978-0-585-38145-9_8

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-7923-8520-2

  • Online ISBN: 978-0-585-38145-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation